Bioxcel Therapeutics shares jump 10.39% intraday after Rodman & Renshaw initiates "Buy" rating with $17 target and FDA filing for at-home use approval.

Bioxcel Therapeutics surged 10.39% intraday after Rodman & Renshaw initiated coverage with a "Buy" rating and a $17 price target, signaling strong investor confidence. The firm also highlighted the company’s recent supplemental new drug application to the FDA for at-home use of its treatment for acute bipolar agitation, underscoring regulatory progress. These developments aligned with positive market sentiment, outweighing a separate, unrelated price target reduction by H.C. to $6. The stock’s sharp intraday gain reflects optimism over the FDA filing and institutional endorsement of its growth potential.